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Abstract
Background: Data have indicated that the lymph node ratio (LNR) may be a better prognostic indicator
than lymph node status in pancreatic cancer.
Objectives: To analyse the value of the LNR in patients undergoing resection for periampullary
carcinomas.
Methods: A cut off value of 0.2 was assigned to the LNR in accordance with published studies. The
impact of histopathological factors including a LNR was analysed using Kaplan–Meier and Cox regression
methods.
Results: In total, 551 patients undergoing a resection (January 2000 to December 2010) were analysed.
The median lymph node yield was 15, and 198 (34%) patients had a LNR > 0.2. In patients with a LNR
of > 0.2, the median overall survival (OS) was 18 versus 33 months in patients with an LNR < 0.2 (P <
0.001). Univariate analysis demonstrated a LNR > 0.2, T and N stage, vascular or perineural invasion,
grade and resection margin status to be significantly associated with OS. On multivariate analysis, only
a LNR > 0.2, vascular or perineural invasion and margin positivity remained significant. In N1 disease, a
LNR was able to distinguish survival in patients with a similar lymph node burden, and correlated with
more aggressive tumour pathological variables.
Conclusion: A LNR > 0.2, and not lymph note status, is an independent prognostic factor for OS
indicating the LNR should be utilized in outcome stratification.
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Introduction
Surgical resection remains the only potential curative treatment
for periampullary cancers (ampulla, pancreatic head, distal
common bile duct and duodenal); however, the 5-year survival
has not improved significantly over the past decade and rarely
exceeds 25%, with better results for ampullary lesions and worse
outcomes for pancreatic head adenocarcinomas.1,2 Several his-
topathological and tumour-related factors have been associated
with a poor prognosis after surgery including tumour stage, size,
grade, DNA content, resection margin and lymph node status.3,4
The potential for more effective chemotherapeutic and biological
agents may require modifications in traditional staging methods
to facilitate effective patient selection for clinical trials, adjuvant
therapies and for the purposes of prognosticatication.
An increasing number of reports are proposing the ratio
between the number of lymph nodemetastases and the number of
resected nodes, the so-called lymph node ratio (LNR), as a prog-
nostic indicator of poor overall survival (OS), suggesting it may be
more important than either LN status or the number of nodes
evaluated alone in pancreatic cancer.5–12 These studies and others
in gastrointestinal cancers have shown that LNR either as a cat-
egorical variable using a cut-off of 0.2 (ranges 0.15–0.4) or as a
continuous variable were strong negative prognostic factors.13,14
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The aim of this study was to analyse the LNR in patients under-
going a resection for periampullary carcinomas, assess its value as
a prognostic factor on OS and evaluate its role in the context of
other established prognostic factors.
Patients and methods
A total of 598 patients underwent a pancreatoduodenectomy at
two high volume institutions; the Cleveland Clinic, Cleveland,
Ohio, USA and St James University Hospital, Leeds, England
between January 2000 and December 2010. Periampullary carci-
nomas comprised of tumours of the pancreatic head, ampulla
complex and distal common bile duct. Duodenal carcinomas were
excluded from this study.
In all patients, pre-operative radiological assessment included a
thoracic, abdominal and pelvic computed tomography (CT), with
magnetic resonance imaging of the pancreas and biliary tree per-
formed when indicated. Operative techniques are similar at the
two centres including the dissection of the pancreatic head and
peri-pancreatic lymph nodes, and in the restoration of continuity
of the gastrointestinal tract. A standard lymphadenectomy was
performed in all patients. There were no differences in unit pro-
tocols directed decisions on the use of blood products with trans-
fusion of red blood cells performed for those with haemoglobin
<8 g/dl or symptomatic patients with haemoglobin of 8–10 g/dl.
For each patient, a demographic profile was collected together
with details of histopathological features including resection
margin status, vascular and perineural invasion. For all specimens,
the total number of lymph nodes retrieved was recorded, as were
the number with metastatic involvement. The American Joint
Committee on Cancer (AJCC) TNM classification and the Royal
College of Pathologist of United Kingdom have set 12 and 15
lymph nodes, respectively, as the minimal number to be collected
at surgery and these figures were utilized to create categorical
variables for the survival analysis.15,16 For the purpose of this study,
a positive resection margin was defined as the presence of a cancer
cell within 1 mm of the transection margins.
The LNR was calculated by dividing the number of lymph
nodes with metastasis present by the number of lymph nodes
examined. For the main analysis, patients were divided into two
groups according to a LNR either below or above 0.2. This was
selected after review of the literature and utilized to maintain
some uniformity when comparing with published studies. In
addition, a further analysis was performed using different LNR
cut-offs to evaluate the impact on OS and in patients with N1
disease.
Survival and follow-up
Peri-operative mortality was defined as death within 60 days after
a resection and such patients were excluded from long-term sur-
vival analysis.17 After initial post-operative review at 1 month, all
patients were examined in the outpatient clinic at 3-monthly
intervals for the first 2 years and annually thereafter. Overall sur-
vival was defined from the time of surgical resection to the date of
death.
Data collection and statistical analysis
Student’s t-test and Pearson’s chi-squared test was used for con-
tinuous and categorical variables, respectively. Where variables
did not follow a normal distribution, the Mann–Whitney U-test
was applied. The Kaplan–Meier method was performed to analyse
the overall survival. A multi-variate analysis was performed using
Cox regression (Step-wise forward model) for variables reaching
significance on univariate analysis that impacted upon OS.
All statistical analyses were performed using the PASW for
Windows™ version 18.0 (SPSS Inc, Chicago, IL, USA), and statis-
tical significance was taken at the 5% level.
Results
During the study period, 598 patients underwent surgery for peri-
ampullary carcinomas. The complete datasets were not available
for 5 (0.8%) patients, and together with peri-operative mortality
of 42/593 (7%) the total number of patients available for the
analysis of long-term survival was 551 (92.1%). Descriptive data
for the entire cohort are shown in Table 1.
Long-term survival
The median follow-up was 32 months (range 0–130) and the
median OS for the entire study cohort was 26 months (range
21–30). At the time of the analysis, 238 (40%) patients were still
alive. Actuarial overall 1-, 3- and 5-year survival for the study
group was 77% 39% and 27% respectively. Patient and tumour
variables in the entire group of patients divided by the LNR < 0.2
and > 0.2 are shown in Table 2. The analysis of factors associated
with OS is summarized in Table 3.
LNR, nodal status and OS
A LNR > 0.2 was an independent prognostic indicator of a poor
outcome conferring an increased risk of death in the study popu-
lation (n = 551) by 37% (HR 1.373,P = 0.030) Table 3. Themedian
survival for patients with a NLR < 0.2 was 33 months compared
with 18 months in patients with a LNR > 0.2 (P < 0.001) Fig. 1. In
an attempt tomake an observation on the impact of different LNR
cut-offs on outcome, the median survival was assessed for incre-
mental increases in LNR, and an inverse relationship between
these factors was observed: > 0.05, > 0.1, > 0.15, > 0.2 and > 0.3
associated with 33, 20, 21, 18 and 18 months, respectively (P <
0.001). The cut-off value for when LNR loses its value as an
independent in a multivariate model was calculated as 0.08
(1.613 HR 1.076–2.419, P = 0.021, data not shown). A Kaplan–
Meier curve for OS stratified by different LNR cut-off values (0.05,
0.1, 0.15, 0.2, 0.3) is shown in Fig. 2 and the 3-year actuarial
survival was 42%, 36%, 27%, 23% and 22% for each cut-off
respectively.
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Table 1 Demographics, operative and histopathological data of
entire cohort
Variable
Age, years
<65s 254 (43%)
>65 339 (57%)
Gender
Female 261 (44%)
Male 332 (56%)
Pre-operative biliary stenting
Yes 460 (78%)
No 133 (22%)
Tumour size (mm) mean ( SD) 28  13
Tumour size
<30 337 (57%)
>30 256 (43%)
Grade
1 48 (8%)
2 268 (45%)
3 268 (45%)
4 7 (2%)
Tumour stage
1 40 (8%)
2 129 (21%)
3 389 (67%)
4 35 (6%)
Node
0 189 (32%)
1 404 (68%)
No of examined LN (median, IQR) 15 (8–21)
No of metastatic LN (median) 2
LNR
Median 0.18
0–0.04 209 (35%)
0.05–0.09 74 (13%)
0.1–0.14 65 (11%)
0.15–0.199 47 (8%)
0.2–0.299 71 (12%)
>0.3 127 (21%)
Vascular invasion
No 218 (37%)
Yes 375 (63%)
Perineural invasion
No 174 (30%)
Yes 418 (70%)
Resection margin
R0 466 (79%)
R1 127 (21%)
LNR, lymph node ratio; IQR, interquartile range.
Table 2 Variables associated with LNRs of <0.2 and 0.2 in the
entire cohort
Variable LNR <0.2 LNR 0.2 P
N (593) 394 (66%) 198 (34%)
Age, years
<65 167 (42%) 87 (44%)
65 227 (58%) 111 (56%) 0.79
Gender
Female 179 (45%) 82 (41%)
Male 215 (55%) 116 (59%) 0.353
Pre-operative biliary stenting
No 109 (48%) 88 (44%)
Yes 204 (52%) 110 (56%) 0.569
Tumour size, mm
<30 245 (62%) 92 (46%)
>30 149 (38%) 106 (54%) <0.001
Grade
1 37 (9%) 11 (5%)
2 179 (45%) 88 (44%)
3 169 (42%) 99 (51%)
4 7 (4%) 0 0.06
Tumour stage
1 30 (8%) 11(6%)
2 101 (25%) 28 (14%)
3 243 (61%) 144 (73%) 0.003
4 20 (6%) 15 (8%)
No of examined LN (median,
IQR)
15 (8–21) 16 (9–22) 0.569
No of examined LN
<12 133 (34%) 58 (30%)
>12 261 (66%) 140 (70%) 0.273
No of examined LN
<15 190 (48%) 90 (45%)
>15 204 (52%) 108 (55%) 0.523
No of metastatic LN
0 191 (41%) 0
1 92 (23%) 12 (6%)
>2 111 (34%) 186 (94%) <0.001
Vascular invasion
No 170 (43%) 48 (24%)
Yes 222 (57%) 153 (76%) <0.001
Perineural invasion
No 135 (35%) 39 (20%)
Yes 259 (65%) 159 (80%) <0.001
Resection margin
R0 323 (81%) 143 (72%)
R1 71 (19%) 55 (28%) 0.006
LN, lymph node.
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Table 3 Overall survival after a resection: uni- and multivariate analysis
Covariant N (551) Univariate P Multivariate P
HR (95% CI) HR (95% CI)
Age, years
<65 241
65 310 1.295 (0.921–1.820) 0.137
Gender
Female 244
Male 307 1.362 (0.970–1.914) 0.075
Pre-operative stent
No 12
Yes 424 1.134 (0.760–1.691) 0.559
Tumour size, mm
<30 318
>30 232 1.315 (0.933–1.855) 0.118
Grade
1 47
2 251 2.005 (1.067–3.768) 0.031 2.172 (1.351–3.493) 0.001
3 243 1.804 (0.959–3.393) 0.061 3.400 (0.999–11.57) 0.051
4 7 1.012 (0.203–5.039) 0.981
Tumour stage
1 37
2 124 1.476 (0.706–3.085) 0.31
3 353 1.790 (0.906–3.536) 0.094
4 31 0.850 (0.324–2.225) 0.740
Node
0 180
1 371 2.046 (1.425–2.937) <0.001 1.142 (0.092–13.874) 0.917
No of examined LN
<12 182
>12 369 1.165 (0.815–1.666) 0.403
No of examined LN
<15 258
>15 293 0.832 (0.593–1.167) 0.287
Involved LN
No 183
Yes 368 2.092 (1.459–2.999) <0.001 1.246 (0.088–9.874) 0.457
No of metastatic LN
0 183
1 99 1.451 (0.886–2.374) 0.139
>2 269 2.409 (1.638–3.534) <0.001 2.146 (0.462–9.966) 0.330
LNR cut-off*
<0.05 200
>0.05 351 2.146 (1.507–3.057) <0.001 1.205 (0.592–2.455) 0.607
<0.1 270
>0.1 281 2.258 (1.600–3.187) <0.001 1.435 (1.030–1.997) 0.033
<0.15 338
>0.15 213 2.118 (1.479–3.031) <0.001 1.311 (1.015–1.746) 0.039
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Table 3 Continued
Covariant N (551) Univariate P Multivariate P
HR (95% CI) HR (95% CI)
<0.2 371
>0.2 180 2.253 (1.453–3.297) <0.001 1.373 (1.016–1.854) 0.030
<0.3 432
>0.3 118 2.190 (1.409–3.404) <0.001 1.352 (1.031–1.773) 0.029
Vascular invasion
No 176
Yes 375 1.625 (1.161–2.274) 0.005 1.322 (1.024–1.707) 0.032
Perineural invasion
No 167
Yes 384 2.280 (1.809–4.648) <0.001 1.894 (1.430–2.514) 0.001
Resection margin
R0 438
R1 113 2.900 (1.809–4.645) <0.001 1.457 (1.129–1.880) 0.004
Figure 1 The impact of the lymph node ratio (LNR) 0.2 on overall survival (OS), P < 0.001
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The median number of lymph nodes evaluated in the overall
group was 15 (Table 1). There was no significant change in the
median LN yield over the time period; 14 (2000–2005) versus 16
(2005–2010), P = 0.120. When examined as a continuous LN
number or categorical variable (either 12 or 15) it was not asso-
ciated with OS on univariate analysis (Table 3). Patients with N1
disease (n = 370) had a shorter median OS: 21 months compared
with 48 months P < 0.001 in N0 (n = 181) disease. Furthermore,
the number of positive lymph nodes was associated with a corre-
sponding decrease in OS: N0 = 48 months; 1 positive LN = 30
months (P = 0.038); and 2 lymph nodes = 20 months (P <
0.001). While LN positive status was significant at a univariate
level (HR 2.092 (1.638–3.534), P < 0.001) its inclusion in a mul-
tivariate model failed to reach statistical significance (Table 3).
To investigate the effect of the number of lymph nodes
retrieved on survival in either N0 or N1 disease groups were
divided into either </12 or </15 nodes. In N0 disease, there
was a non-significant trend towards a poorer outcome in terms of
long-term survival in patients who had less than 12 nodes
retrieved (41 months versus 56 months; P = 0.26). There was no
significant difference in long-term outcome in N1 disease if less
than 12 nodes were evaluated (19 months versus 22 months; P =
0.917). When the analysis was repeated with the LN retrieval
cut-off set at 15 there was no difference in outcome for either N0
or N1 disease.
In a subset analysis of N1 (n = 370) disease, the factors shown to
be significant at a univariate level included: grade > 2, > 2 lymph
nodes positive, LNR 0.2, a positive resection margin, and vas-
cular and perineural invasion. Furthermore, all these variables
were shown to be independent prognostic factors impacting on
OS in a multivariate model: grade > 2 [HR 1.688 (1.055–2.700),
P = 0.029], LNR0.2 [HR 1.317 (1.020-1.859) P = 0.037], positive
resection margin [HR 1.456 (1.128–1.878), P = 0.004], vascular
invasion [HR 1.307 (1.009–2.001),P = 0.021] and perineural inva-
Figure 2 Overall survival (OS) stratified according to different lymph node ratio (LNR) cut-off values
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sion [HR 1.895 (1.430–2.511), P < 0.001]. When the LNR cut-off
was replaced by (0.1–0.2), (0.2–0.3), (0.3–0.4) or > 0.4, the LNR
remained an independent prognostic factor in N1 disease.
In evaluating the role of LNR in N1 disease specifically, there
was an observed trend demonstrating poorer OS as the LNR
increased from (0.1–0.2), (0.2–0.3), (0.3–0.4) or > 0.4 and was
associated with median survivals of 21, 18, 16 and 16 months,
respectively (Fig. 3). Furthermore, an increasing LNR was shown
to be able to differentiate long-term survival in patients with
similar LN involvement (Table 4) and progressive tumour features
(Table 5).
Discussion
This study has confirmed that a LNR (> 0.2), together with vas-
cular or perineural invasion, and a positive resection margin are
all independent prognostic factors in determining long-term sur-
vival in patients undergoing resection for periampullary tumours.
Additionally, results have demonstrated a progressively poor
outcome in terms of both the overall cohort, and specifically in N1
disease, as the LNR increases from 0.1 to > 0.3.
Figure 3 Overall survival (OS) stratified according to different lymph node ratio (LNR) cut-off values in N1 disease
Table 4 The median survival stratified by lymph node ratio (LNR)
cut-off values in N1 disease involving a similar lymph node burden
N LNR
(0.01–0.2)
months
LNR
(0.2–0.4)
months
LNR
>0.4
months
P
LN +ve 0–3 210 24 18 16 0.730
LN +ve 4–5 72 27 25 13 0.0201
LN +ve >6 85 16 15 12 0.052
LN +ve = lymph node positivity.
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The presence of nodal disease represents a poor prognostic
factor,18 is associated with relatively high rates of LN metastasis to
para-aortic nodal stations in periampullary tumours19,20 and, in
the current study, has been shown to confer poorer OS than N0
disease. Results confirm House et al.’s observation that as the
number of involved LN increases2 there is an associated reduc-
tion in OS.21 Importantly, however, in spite of the presence of
nodal disease, or more specifically 2 nodes involved being asso-
ciated with poor OS on a univariate level, it failed as an independ-
ent prognostic factor in a multivariate model herein and concurs
with previous studies.7,10,22
Several authors have previously advocated performing an
extended lymphadenectomy to improve lymphatic clearance and
the potential prognosis.23,24 A number of systematic reviews, ran-
domized controlled trials and meta-analyses including a recent
study describing 16 studies containing 1909 patients refute this
approach and show no survival advantage associated with an
extended pancreatoduodenectomy compared with a standard
lymphadenectomy.25,26 Furthermore, given the predicted small dif-
ference in outcome, the number of patients required to show a
statistically significant difference between a standard and
extended lymphadenectomy would be so large that such an
adequately powered randomized controlled trial would be
unfeasible.27
Pawlik et al. demonstrated that less than 12 nodes retrieved in
N0 disease resulted in poorer OS and Tomlinson and colleagues
highlighted that 15 nodes were required to confer a survival
advantage in N0 disease.9,28 The number of lymph nodes required
to minimize the risk of the stage migration phenomenon is pro-
posed to be between 10 and 15.29,30 In this study, the impact of
achieving a LN yield of both the American Joint Committee on
Cancer (AJCC) TNM classification and the Royal College of
Pathologist of United Kingdom criteria which are 12 and 15,
respectively, is reported.15,16 While there was an observed trend
towards poorer OS in N0 disease with < 12 nodes retrieved there
was no statistical significance in OS when either >15 nodes in N0
or >12 & >15 nodes obtained in N1 disease. Furthermore, the
analysis of the number of lymph nodes as a categorical value of 12
or 15 (or indeed as a continuous variable, data not shown) failed
to show any correlation in a univariate analysis.
Several investigators have attempted to explore the relevance of
not only the number of examined LN but also the utility of the
LNR in various gastrointestinal cancers including oesophageal,
gastric, colorectal and pancreatic carcinoma.31 By definition, this
marker incorporates both the extent of the metastatic disease
(number of positive LN), the quality of a lymphadenectomy and
the provision of an adequate specimen for the pathologist (the
number of LN retrieved). In stage 3 colorectal cancer, the LNR
provides a superior and independent prognostic stratification
compared with the assessment of the number of positive nodes.31
In pancreatic cancer, there have been a number of studies (pre-
dominantly incorporating case series of around 50–100 patients)
that have reported the negative impact of an LNR range of
between 0.10–0.40 on long-term outcomes.6–8,10,11,22,32–35 The
current study includes more than 500 patients and it follows only
three others with larger numbers.9,12,21
No consensus has been established for the most prognostically
accurate cut-off of LNR but in a review of the literature it appears
to centre around 0.2 and its variance probably is a reflection of
multiple components including tumour biology, an adequate
lymphadenectomy and pathological examination the specimen to
achieve maximum LN yield. House et al. in their study of 906
patients analysed LNR as a continuous variable and determined a
cut-off value of 0.18 in predicting outcome.21 The median survival
of patients with an NLR < 0.2 in the current study was 33 months
which was significantly greater than the 18 months in those with
an LNR of >0.2 and results demonstrate a decrease in OS as LNR
increases. Furthermore, in keeping with the findings of both
Pawlik et al. and Bhatti et al., the current data demonstrated that
the LNR is a valid marker for predicting adverse tumour factors
such as vascular and perineural invasion and a positive resection
margin.7,9
Tissue processing and meticulous pathological assessment are
now becoming part of robust protocols in establishing true resec-
tion margin status and challenging marked variability in LN
counts in tissue.36–38 The technique now being adopted globally for
the histological assessment of pancreatic specimens was devel-
oped in Leeds and introduced into practice in the Cleveland Clinic
in 2009.39 While all the Leeds specimens were processed using the
new technique, it was only in the later period of the study was it
used in both centres and to remove this as a confounding factor,
the definition of positive margins was that traditionally utilized
namely the presence of a tumour at the surgical resection margins
rather than the new concept which also addresses in detail non-
surgical resection margins. As there is no difference in the surgical
treatment of the specimen, it was not felt that this would influence
LN harvest and hence the LNR. Indeed this has been confirmed by
Liska et al.38 Another factor clearly evident when the new method
of tissue sectioning is applied is a change in the origin of the
Table 5 Variation in tumour features as the lymph node ratio (LNR)
increases
LNR
(0.01–0.2)
(%)
LNR
(0.2–0.4)
(%)
LNR
>0.4
(%)
P
Resection margin +ve 17 20 35 0.012
Vascular invasion 32 41 52 0.051
Perineural invasion 69 75 83 0.035
Size >30 mm 48 52 55 0.599
Grade
1 6 4 8 0.575
2 44 46 44
3 47 50 48
4 3 0 0
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periampullary tumours. The data from Leeds would suggest that
with the new technique of histopathological examination, which
allows a more accurate assessment of the periampullary region,
the proportion of pancreatic, ampullary and ductal carcinomas is
close to equal, whereas traditional methods of tissue preparation
would suggest a predominance of pancreatic head lesions. Conse-
quently to avoid an inaccurate representation, periampullary car-
cinomas are not categorized individually and included in a
multivariate analysis in this study. This is in difference to previous
studies and acknowledges that some would consider this as a
limitation.
There are in addition other limitations of the study. It is difficult
to accurately account for surgical decision-making in performing
more extensive LN dissections between different surgeons/centres
in specific patients and not others. However, the finding that
neither the number of lymph nodes retrieved or the proportion
with >12 nodes harvested has not altered over time would lead us
to assume that the technique has not significantly changed in the
study period. It could be argued that the observation of a poorer
OS in N0 disease where less than 12 nodes were retrieved could
have represented missing nodes but as there was no correlation
between the number of LN examined and outcome in the statis-
tical model, it would appear that under-staging does not account
for this, or if it is involved its influence is weak. The role of
adjuvant chemotherapy has not been studied in this study as there
was significant variation in its use across the 10 years of the study
in relation to whether it was offered or not, and the constituents of
the treatment.
The study is retrospective and hence there are questions as to
data interpretation in particular in relation to some of the finer
aspects of pathological assessment as at the commencement of the
study therewas no sub-specialization in pancreatic histopathology.
However, in spite of this, the increasing number of retrospective
studies that now exist in this subject area means that there is now
the need for prospective studies in collaboration with potential
adjuvant treatments to provide the next level of evidence in estab-
lishing the most optimal cut off value for LNR, utility as a negative
prognostic factor and deciding on treatment algorithms.32
Conclusions
A LN ratio > 0.2 (and not LN status or LN yield) is, together with
neurovascular invasion, and resection margin an important inde-
pendent prognostic factors for OS in periampullary carcinomas.
These data, in a large series, confirms previous studies in leading
to the proposal of its utilization in outcome stratification.
Prospective studies are now required to determine whether the
LNR can be used to predict the need for, and benefit from
chemotherapy.
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